Mizuho Securities analyst Salim Syed maintained a Buy rating on Wave Life Sciences (WVE) today and set a price target of $65. The company’s shares opened today at $27.40, close to its 52-week low of $22.90.
Syed observed:
“We were joined by Paul Bolno (CEO) and Kate Rausch (IR). We saw both long-onlies and hedge funds, some deep in the weeds on the story, and some new to it.”
According to TipRanks.com, Syed is a 1-star analyst with an average return of -2.1% and a 40.4% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Gilead Sciences.
Wave Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $41.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $56 and a one-year low of $22.90. Currently, Wave Life Sciences has an average volume of 476.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
